Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea
At ASH 2014, Dr. Srdan Verstovsek discussed his abstract titled Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea (Abstract 1847).
Recent Video
Most Popular
Specialties :                    Search :


MPNUniversity.tv is a member of the Oncology.TV family of oncology medical education websites. MPNUniversity.tv offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).